Search results for "fat"

showing 10 items of 4644 documents

Hyperuricemia in non-alcoholic fatty liver disease: authors’ reply

2011

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinePharmacology (medical)HyperuricemiabusinessAlimentary Pharmacology & Therapeutics
researchProduct

Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease

2011

SUMMARY Background Hyperuricemia has been associated with metabolic disorders. In this line recent studies observed an independent link between higher uric acid serum levels and clinical diagnosis of non-alcoholic fatty liver disease (NAFLD). Mean uric acid serum level was 5.75 mg ⁄ dL, and about 20% of patients had hyperuricemia, that was independently associated with younger age (OR 0.951, 95% CI 0.918-0.984, P = 0.004), lobular inflammation (OR 2.144, 95% CI 1.055-4.357, P = 0.03) and steatosis grade (OR 1.859, 95% CI 1.078-3.205, P = 0.02), by multivariate logistic regression analysis. Female gender (OR 2.656, 95% CI 1.190-5.928, P = 0.01), higher HOMA index (OR 1.219, 95% CI 1.043- 1.4…

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseLogistic regressionGastroenterologyEndocrinologyInternal medicineMedicinePharmacology (medical)In patientHyperuricemiaLiver damageSteatosisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

P1013 : Chronic intermittent hypoxia is associated with liver damage and atherosclerosis in patients with non-alcoholic fatty liver disease

2015

all the steatosis grades, except S2 vs S3. The diagnostic performances of CAP in quantifying each steatosis grade was: for S ≥1 AUC=0.813 (cutoff 260dB/m, Se = 64.84%, Sp =87.27%, PPV=80.8%, NPV=75%, +LR =5.09, −LR =0.40, DA=76.11%); for S ≥2 AUC=0.822 (cutoff 285dB/m, Se = 69.70%, Sp =85.12%, PPV=47.9%, NPV=93.5%, +LR =4.68, −LR =0.36, DA=82.08%); for S ≥3 AUC=0.838 (cutoff 294dB/m, Se =83.33%, Sp =82.54%, PPV=23.3%, NPV=98.7%, +LR =4.77, −LR =0.20, DA=81.59%). AUCs calculated between two steatosis grades only were: 0.772 (for S0 vs S1), 0.874 (S0 vs S2), 0.904 (S0 vs S3), 0.659 (S1 vs S2), 0.777 (S1 vs S3), and 0.665 (S2 vs S3) respectively. Conclusions: Maximal diagnostic accuracy could …

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicineCutoffChronic intermittent hypoxiaIn patientLiver damageSteatosisbusinessJournal of Hepatology
researchProduct

Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non‐alcoholic fatty liver disease—the role for non‐invasive testing

2021

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon invasiveGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyText miningInternal medicinemedicinePharmacology (medical)In patientbusinessHepatic fibrosisCoronary atherosclerosisAlimentary Pharmacology & Therapeutics
researchProduct

Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?

2012

--

medicine.medical_specialtyHepatologybusiness.industryFibrosisInternal medicineNAFLD FIBROSIS FIBROSCANNonalcoholic fatty liver diseasemedicinemedicine.diseasebusinessGastroenterologyLiver pathologyHepatology
researchProduct

FNDC5 rs3480 A>G polymorphism disentangles steatosis from fibrosis severity in patients with nonalcoholic fatty liver disease

2016

S. Petta1, L. Valenti2, R.M. Pipitone1, P. Dongiovanni2, C. Camma1, A.L. Fracanzani2, V. Di Marco1, M. Milano2, S. Grimaudo1, S. Fargion2, A. Craxi1 1 Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Palermo, Italy 2 Department of Pathophysiology and Transplantation, Universita degli Studi, Internal Medicine, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyFNDC5TransplantationFibrosisInternal medicineNonalcoholic fatty liver diseaseMedicineIn patientSteatosisbusinessDigestive and Liver Disease
researchProduct

Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression.

2020

Nonalcoholic fatty liver disease (NAFLD), depression, and anxiety disorders are frequent diseases, and data on mutual influence are inconsistent. The aim of this study was to explore the incidence of depression and anxiety in a large primary care cohort in Germany and to study the impact of NAFLD over a 10‐year time frame. Patients with NAFLD diagnosed between 2010 and 2015 were matched to a cohort without NAFLD controlling for age, sex, physician, index year, and Charlson comorbidity index. The primary outcome of the study was the incidence of depression, anxiety, and first prescription of antidepressant drugs. We compared 19,871 patients with NAFLD to 19,871 matched controls. Within 10 ye…

medicine.medical_specialtyHepatologybusiness.industryIncidence (epidemiology)Hazard ratioConfoundingOriginal Articlesmedicine.diseaseInternal medicineNonalcoholic fatty liver diseaseCohortMedicineAnxietylcsh:Diseases of the digestive system. GastroenterologyOriginal Articlelcsh:RC799-869medicine.symptomRisk factorbusinessDepression (differential diagnoses)Hepatology communications
researchProduct

OC.03.2 THE PRESENCE OF WHITE MATTER LESIONS IS ASSOCIATED WITH THE HISTOLOGICAL SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE

2016

medicine.medical_specialtyHepatologybusiness.industryInternal medicineFatty liverGastroenterologyMedicineNon alcoholicDiseasebusinessmedicine.diseaseGastroenterologyHyperintensityDigestive and Liver Disease
researchProduct

Early menopausal status is associated with the severity of liver fibrosis in Italian patients with non-alcoholic fatty liver disease

2014

medicine.medical_specialtyHepatologybusiness.industrySettore MED/12 - GASTROENTEROLOGIALiver fibrosisFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinebusinessDigestive and Liver Disease
researchProduct

Visceral adiposity index and exercise in non-alcoholic fatty liver disease: authors’ reply

2012

We thank Prof. Filik for his interest in our recent article. 2 He points to the fact that the interpretation of our results could be affected by lack of data on physical activity and diet. In response to this issue, we are aware that both physical activity and diet are able to affect not only anthropometric and metabolic parameters of visceral adiposity index (VAI) but also the severity of liver disease. Unfortunately, data on both physical activity and diet in our patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD) are not available, even if we are confident that their variations should not significantly affect our results. In fact, in our study, we evaluated histological…

medicine.medical_specialtyHepatologybusiness.industrySurrogate endpointFatty liverGastroenterologyNon alcoholicDiseaseAnthropometrymedicine.diseaseGastroenterologyLiver diseaseEndocrinologyInternal medicineMedicinePharmacology (medical)Liver damagebusinessMETABOLIC FEATURESAlimentary Pharmacology & Therapeutics
researchProduct